Post-acute COVID-19 in three doses vaccinated autoimmune rheumatic diseases patients: frequency and pattern of this condition

BACKGROUND: Data on post-acute COVID-19 in autoimmune rheumatic diseases (ARD) are scarce, focusing on a single disease, with variable definitions of this condition and time of vaccination. The aim of this study was to evaluate the frequency and pattern of post-acute COVID-19 in vaccinated patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Clovis Artur, de Vinci Kanda Kupa, Leonard, Medeiros-Ribeiro, Ana Cristina, Pasoto, Sandra Gofinet, Saad, Carla Gonçalves Schahin, Yuki, Emily Figueiredo Neves, Landim, Joaquim Ivo Vasques Dantas, Léda, Victor Hugo Ferreira e, de Camargo Correia, Luisa Sacchi, Sartori, Artur Fonseca, Martins, Carolina Campagnoli Machado Freire, Ribeiro, Carolina Torres, Waridel, Filipe, de Oliveira Martins, Victor Adriano, Shinjo, Samuel Katsuyuki, Andrade, Danieli Castro Oliveira, Barros, Percival Degrava Sampaio, Neto, Eduardo Ferreira Borba, Aikawa, Nadia Emi, Bonfa, Eloisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248954/
https://www.ncbi.nlm.nih.gov/pubmed/37291679
http://dx.doi.org/10.1186/s42358-023-00309-z
Descripción
Sumario:BACKGROUND: Data on post-acute COVID-19 in autoimmune rheumatic diseases (ARD) are scarce, focusing on a single disease, with variable definitions of this condition and time of vaccination. The aim of this study was to evaluate the frequency and pattern of post-acute COVID-19 in vaccinated patients with ARD using established diagnosis criteria. METHODS: Retrospective evaluation of a prospective cohort of 108 ARD patients and 32 non-ARD controls, diagnosed with SARS-CoV-2 infection (RT-PCR/antigen test) after the third dose of the CoronaVac vaccine. Post-acute COVID-19 (≥ 4 weeks and > 12 weeks of SARS-CoV-2 symptoms) were registered according to the established international criteria. RESULTS: ARD patients and non-ARD controls, balanced for age and sex, had high and comparable frequencies of ≥ 4 weeks post-acute COVID-19 (58.3% vs. 53.1%, p = 0.6854) and > 12 weeks post-acute COVID-19 (39.8% vs. 46.9%, p = 0.5419). Regarding ≥ 4 weeks post-acute COVID-19, frequencies of ≥ 3 symptoms were similar in ARD and non-ARD controls (54% vs. 41.2%, p = 0.7886), and this was also similar in > 12 weeks post-acute COVID-19 (68.3% vs. 88.2%, p = 0.1322). Further analysis of the risk factors for ≥ 4 weeks post-acute COVID-19 in ARD patients revealed that age, sex, clinical severity of COVID-19, reinfection, and autoimmune diseases were not associated with this condition (p > 0.05). The clinical manifestations of post-acute COVID-19 were similar in both groups (p > 0.05), with fatigue and memory loss being the most frequent manifestations. CONCLUSION: We provide novel data demonstrating that immune/inflammatory ARD disturbances after third dose vaccination do not seem to be a major determinant of post-acute COVID-19 since its pattern is very similar to that of the general population. Clinical Trials platform (NCT04754698). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42358-023-00309-z.

Ejemplares similares